HLB Therapeutics to raise 11.18B KRW via rights issue
HLB테라퓨틱스
115450
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2705
Risk-adjusted indicator based on 2705 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Total Funding: 11,181,035,000 KRW
- • Issuance Price per Share: 1,832 KRW
- • Payment Date: August 20, 2026
- • 17th CB Offset Amount: 6,106,299,000 KRW
- • 18th CB Offset Amount: 5,074,736,000 KRW
AI Analysis Summary
HLB Therapeutics announced a paid-in capital increase to raise 11.18 billion KRW. The funds will be raised through a third-party allocation, with the issuance price set at 1,832 KRW per share. The payment date is August 20, 2026. The capital increase will be settled by offsetting existing debts from the 17th and 18th series of private convertible bonds held by HLB Co., Ltd., totaling 6.11 billion KRW and 5.07 billion KRW, respectively. The newly issued shares will be subject to a one-year lock-up period. This transaction primarily converts debt to equity, which is generally neutral for cash flow but could impact future EPS.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.